A second aspect of the positive data for women seen in the previous Figure is the representation of females in the pivotal clinical trials of the NOACs: as shown in the Figure this has been high by historical standards, in the 35-40% range.[121] [125] [129] This ensures that, going forward, it will be possible to optimize the understanding of the NOACs in females, which is important because it reflects the higher risk of disease events, and the greater benefit of therapy, in women (and the elderly) in clinical practice.

French WJ. Am J Med 2013; 126: 00-00.